{"id":5933,"date":"2025-01-20T10:03:06","date_gmt":"2025-01-20T16:03:06","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5933"},"modified":"2025-07-13T15:11:42","modified_gmt":"2025-07-13T20:11:42","slug":"nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2025\/01\/20\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\/","title":{"rendered":"Nanoscope Therapeutics se presentar\u00e1 en la 21.\u00aa Conferencia Anual de la Semana de Terapias Avanzadas"},"content":{"rendered":"
\n
\n
\n
\n
\n

<\/h1>\n<\/div>\n
\n
\n

DALLAS<\/span><\/span>,\u00a020 de enero de 2025<\/span><\/span> \u2014\u00a0Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con la restauraci\u00f3n de la visi\u00f3n en pacientes ciegos en entornos del mundo real mediante el desarrollo y la comercializaci\u00f3n de nuevas terapias gen\u00e9ticas para enfermedades degenerativas de la retina, anunci\u00f3 hoy varias presentaciones de los l\u00edderes de la empresa en el\u00a021calle<\/sup>\u00a0\u00a0Conferencia Anual de la Semana de Terapias Avanzadas<\/a>, que tendr\u00e1 lugar del 20 al 23 de enero de 2025 en el Centro de Convenciones Kay Bailey Hutchinson en\u00a0Dallas, Texas<\/span>. Los detalles de las presentaciones son los siguientes:<\/p>\n

T\u00edtulo:<\/b>\u00a0C\u00f3mo afrontar los desaf\u00edos de las terapias gen\u00e9ticas para enfermedades raras
\nT\u00edtulo de la sesi\u00f3n:\u00a0<\/b>Terapia g\u00e9nica para enfermedades raras
Fecha de la sesi\u00f3n:\u00a0<\/b>21 de enero de 2025<\/span>
Tiempo de sesi\u00f3n:\u00a0<\/b>12:15 pm hora central<\/span>
Presentador:\u00a0<\/b>Samarendra Mohanty<\/span>, Doctor en Filosof\u00eda, Presidente y Director Cient\u00edfico<\/p>\n

El Dr. Mohanty hablar\u00e1 sobre los desaf\u00edos clave que enfrentan los programas de terapia g\u00e9nica modernos para las indicaciones de enfermedades raras. Entre ellos, se incluyen la falta general de modelos animales adecuados, criterios de valoraci\u00f3n cl\u00ednicos establecidos y procesos de fabricaci\u00f3n y an\u00e1lisis validados, que en la mayor\u00eda de los casos deben ser implementados por el desarrollador de la terapia g\u00e9nica.<\/p>\n

T\u00edtulo:<\/b>\u00a0Asociarse para la comercializaci\u00f3n, una perspectiva de CMC
\nT\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Colaboraci\u00f3n para el \u00e9xito de la terapia gen\u00e9tica
Fecha de la sesi\u00f3n:<\/b>\u00a021 de enero de 2025
Tiempo de sesi\u00f3n:<\/b>\u00a04:30 pm hora central
Presentador:<\/b>\u00a0Raymond Kaczmarek, director t\u00e9cnico y de fabricaci\u00f3n<\/p>\n

Durante su presentaci\u00f3n, el Sr. Kaczmarek destacar\u00e1 varias consideraciones internas y externas clave que son primordiales para garantizar una relaci\u00f3n CDMO exitosa y un programa de fabricaci\u00f3n general para programas de terapia gen\u00e9tica.<\/p>\n

T\u00edtulo de la sesi\u00f3n:\u00a0<\/b>Convergencia internacional y alineamiento regulatorio para el impuesto sobre la renta de las personas f\u00edsicas
Fecha de la sesi\u00f3n:\u00a0<\/b>22 de enero de 2025<\/span>
Tiempo de sesi\u00f3n:\u00a0<\/b>11:00 am hora central<\/span>
Silla:\u00a0<\/b>Khandan Baradaran<\/span>, PhD, SVP Regulatorio y Calidad<\/p>\n

El Dr. Baradaran organizar\u00e1 una charla informal con el Dr.\u00a0Nicole Verd\u00fan<\/span>, Director de la Oficina de Productos Terap\u00e9uticos del CBER, analiza c\u00f3mo los desarrolladores de terapias gen\u00e9ticas y celulares pueden forjar interacciones productivas con los reguladores para garantizar un camino eficiente hacia la aprobaci\u00f3n.<\/p>\n

T\u00edtulo:<\/b>\u00a0Enfoques \u00f3pticos para terapias g\u00e9nicas resolubles no virales
\nT\u00edtulo de la sesi\u00f3n:\u00a0<\/b>\u00bfSe vislumbran en el horizonte terapias gen\u00e9ticas reutilizables?
\nFecha de la sesi\u00f3n:\u00a0<\/b>22 de enero de 2025<\/span>
Tiempo de sesi\u00f3n:\u00a0<\/b>11:00 am hora central<\/span>
Presentador:\u00a0<\/b>Subrata Batabyal<\/span>, PhD, Director, Desarrollo no cl\u00ednico<\/p>\n

Durante su presentaci\u00f3n, el Dr. Batabyal hablar\u00e1 sobre las limitaciones de dosificaci\u00f3n de las terapias g\u00e9nicas con AAV y c\u00f3mo las tecnolog\u00edas de dosificaci\u00f3n \u00f3ptica no virales de Nanoscope pueden superar esta limitaci\u00f3n eliminando las preocupaciones relacionadas con la inmunogenicidad.<\/p>\n

T\u00edtulo:<\/b>\u00a0Terapias gen\u00e9ticas de primera l\u00ednea para la ceguera hereditaria
\n<\/b>T\u00edtulo de la sesi\u00f3n:\u00a0<\/b>Presentaciones de empresas de la serie Innovaci\u00f3n
\nFecha de la sesi\u00f3n:\u00a0<\/b>22 de enero de 2025<\/span>
Tiempo de sesi\u00f3n:\u00a0<\/b>4:00 p. m., hora central<\/span>
Presentador:\u00a0<\/b>Sulagna Bhattacharya<\/span>, Director Ejecutivo<\/p>\n

Durante su intervenci\u00f3n, la Sra. Bhattacharya ofrecer\u00e1 una actualizaci\u00f3n corporativa sobre los avances recientes y futuros de Nanoscope en sus programas en desarrollo. En concreto, abordar\u00e1 el principal f\u00e1rmaco de Nanoscope, MCO-010, cuya solicitud de licencia biol\u00f3gica (BLA) est\u00e1 prevista, as\u00ed como el avance del programa Stargardt de Nanoscope a la fase 3 de ensayos cl\u00ednicos para su registro.<\/p>\n

T\u00edtulo:<\/b>\u00a0Garantizar la flexibilidad y la escalabilidad en la fabricaci\u00f3n de terapias g\u00e9nicas con AAV
\nT\u00edtulo de la sesi\u00f3n:\u00a0<\/b>Flujos de trabajo y an\u00e1lisis de bioprocesos para mayor flexibilidad y escalabilidad.
Fecha de la sesi\u00f3n:\u00a0<\/b>22 de enero de 2025<\/span>
Tiempo de sesi\u00f3n:\u00a0<\/b>5:00 pm hora central<\/span>
Presentador:\u00a0<\/b>Victor Adeniyi<\/span>Director s\u00e9nior, CMC<\/p>\n

Durante su presentaci\u00f3n, Adeniyi brindar\u00e1 una descripci\u00f3n general del panorama de los desaf\u00edos anal\u00edticos y de escalabilidad en la terapia gen\u00e9tica, y discutir\u00e1 el valor de dise\u00f1ar e incorporar flexibilidad para abordar estos desaf\u00edos a lo largo del tiempo.<\/p>\n

Acerca de Nanoscope Therapeutics Inc.
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la visi\u00f3n y que no dependen de los genes para los millones de pacientes que han perdido la visi\u00f3n a causa de enfermedades degenerativas de la retina, para las que actualmente no existe cura. Tras los resultados positivos de final de estudio del ensayo cl\u00ednico RESTORE de fase 2b, multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para la RP (NCT04945772<\/a>), la compa\u00f1\u00eda anunci\u00f3 su plan de iniciar un\u00a0Presentaci\u00f3n de BLA para MCO-010 para tratar RP<\/a>\u00a0en el primer trimestre de 2025. La empresa ha completado el ensayo STARLIGHT de fase 2 de la terapia MCO-010 en pacientes con Stargardt (NCT05417126<\/a>) y planea iniciar una\u00a0Ensayo de registro de fase 3<\/a>\u00a0en el primer trimestre de 2025. MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para RP como para Stargardt. Los programas precl\u00ednicos incluyen un activo MCO-020 no viral administrado por l\u00e1ser listo para IND para GA, as\u00ed como un activo AAV para amaurosis cong\u00e9nita de Leber, en estudios que permiten IND.<\/p>\n

Contacto de inversores:<\/b>
Socios Argot
212-600-1902
PR@nanostherapeutics.com<\/a><\/p>\n

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n

\"\"<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0Jan. 20, 2025 \u2014\u00a0Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced several presentations by company leadership at the\u00a021st\u00a0\u00a0Annual Advanced Therapies Week Conference, taking place from\u00a0January 20-23, 2025 at the\u00a0Kay Bailey Hutchinson Convention Center in\u00a0Dallas, […]<\/p>\n","protected":false},"author":6,"featured_media":5934,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5933","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics to Present at the 21st Annual Advanced Therapies Week Conference - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2025\/01\/20\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present at the 21st Annual Advanced Therapies Week Conference - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2025\/01\/20\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-20T16:03:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-13T20:11:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/01\/NSCOPE_LinkedIn_ADVTHERA25.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1920\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/01\/NSCOPE_LinkedIn_ADVTHERA25.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/01\\\/20\\\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/01\\\/20\\\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics to Present at the 21st Annual Advanced Therapies Week Conference\",\"datePublished\":\"2025-01-20T16:03:06+00:00\",\"dateModified\":\"2025-07-13T20:11:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/01\\\/20\\\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\\\/\"},\"wordCount\":638,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/01\\\/20\\\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/NSCOPE_LinkedIn_ADVTHERA25.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/01\\\/20\\\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/01\\\/20\\\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\\\/\",\"name\":\"Nanoscope Therapeutics to Present at the 21st Annual Advanced Therapies Week Conference - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/01\\\/20\\\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/01\\\/20\\\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/NSCOPE_LinkedIn_ADVTHERA25.jpg\",\"datePublished\":\"2025-01-20T16:03:06+00:00\",\"dateModified\":\"2025-07-13T20:11:42+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/01\\\/20\\\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/01\\\/20\\\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/01\\\/20\\\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/NSCOPE_LinkedIn_ADVTHERA25.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/NSCOPE_LinkedIn_ADVTHERA25.jpg\",\"width\":1920,\"height\":1920},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/01\\\/20\\\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present at the 21st Annual Advanced Therapies Week Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la 21.\u00aa Conferencia Anual de la Semana de Terapias Avanzadas - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2025\/01\/20\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present at the 21st Annual Advanced Therapies Week Conference - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2025\/01\/20\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-01-20T16:03:06+00:00","article_modified_time":"2025-07-13T20:11:42+00:00","og_image":[{"width":1920,"height":1920,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/01\/NSCOPE_LinkedIn_ADVTHERA25.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/01\/NSCOPE_LinkedIn_ADVTHERA25.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/01\/20\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/01\/20\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics to Present at the 21st Annual Advanced Therapies Week Conference","datePublished":"2025-01-20T16:03:06+00:00","dateModified":"2025-07-13T20:11:42+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/01\/20\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\/"},"wordCount":638,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/01\/20\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/01\/NSCOPE_LinkedIn_ADVTHERA25.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/01\/20\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\/","url":"https:\/\/nanostherapeutics.com\/2025\/01\/20\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\/","name":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la 21.\u00aa Conferencia Anual de la Semana de Terapias Avanzadas - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/01\/20\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/01\/20\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/01\/NSCOPE_LinkedIn_ADVTHERA25.jpg","datePublished":"2025-01-20T16:03:06+00:00","dateModified":"2025-07-13T20:11:42+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/01\/20\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/01\/20\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2025\/01\/20\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/01\/NSCOPE_LinkedIn_ADVTHERA25.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/01\/NSCOPE_LinkedIn_ADVTHERA25.jpg","width":1920,"height":1920},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/01\/20\/nanoscope-therapeutics-to-present-at-the-21st-annual-advanced-therapies-week-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present at the 21st Annual Advanced Therapies Week Conference"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5933"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5933\/revisions"}],"predecessor-version":[{"id":9007,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5933\/revisions\/9007"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5934"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}